Spectral flow: Fresh blood vs fixed blood comparison on our 25 marker panel

About the Webinar

In this webinar, Ramji Srinivasan, CEO and cofounder, explains the advantages of fixed sample processing in spectral flow cytometry. We compared live versus fixed samples across 36 phenotypic populations and 62 state marker subtypes, revealing:

  • 0.97 correlation in population frequencies
  • 0.91 correlation in state marker-positive subset frequencies

Why does this matter?

For immunotherapy developers, managing fresh specimen processing in clinical trials is a significant hurdle, with 10-20% failure rates due to variability in handling and logistics. Fixed sample processing offers powerful solutions to these challenges:

  1. Reduce failure rates by 10-20X: Centralize flow analysis and eliminate the need for a flow lab in every trial location. Consistency is maximized when all samples are processed by the same facility.
  2. Batch sample analysis: Store fixed samples until an entire set (e.g., all timepoints from a single patient) is ready, ensuring consistent data comparison across the study.
  3. Cut costs and increase flexibility: By storing samples at -80°C, you can delay analysis until you’re sure which samples to focus on, reducing upfront processing commitments and expanding your analysis window.

About the Speaker

Before Teiko, Ramji was Cofounder, CEO and Chairman of Counsyl, a women’s health genetic screening laboratory. Counsyl screened over 1M prospective parents, mothers-to-be and women at risk of hereditary cancer. In 2018, Counsyl was acquired by Myriad Genetics, Inc for $375M in cash and stock.

Ramji earned a B.S. in computer science and an M.S. in financial mathematics, both from Stanford University. Ramji also attended Stanford’s Graduate School of Business before dropping out to start Counsyl.

You Might Also Like

Spectral Flow Essentials: Comparing conventional flow to full spectrum flow cytometry

About the Webinar

In this “essentials” series, Ramji Srinivasan, CEO and cofounder, explains the physical differences between spectral flow cytometry and conventional flow cytometry. Specifically he reviews how these instruments differ in their respective cpacity to measure immune parameters, and why an immunotherapy developer might care. He delves into why these technical differences are, particularly in terms of gaining deeper insights into complex immune cell populations, tracking subtle changes in cell activation states, and identifying biomarkers related to therapeutic response and adverse events.

About the Speaker

Before Teiko, Ramji was Cofounder, CEO and Chairman of Counsyl, a women’s health genetic screening laboratory. Counsyl screened over 1M prospective parents, mothers-to-be and women at risk of hereditary cancer. In 2018, Counsyl was acquired by Myriad Genetics, Inc for $375M in cash and stock.

Ramji earned a B.S. in computer science and an M.S. in financial mathematics, both from Stanford University. Ramji also attended Stanford’s Graduate School of Business before dropping out to start Counsyl.

You Might Also Like

Cytek 25 Marker PBMC Validation

About the Webinar

In this webinar, Ramji Srinivasan, CEO and Cofounder, presents detailed precision and stability data for our 25-marker spectral flow cytometry panel, designed for immune profiling peripheral blood mononuclear cells (PBMCs) from healthy human blood samples.  

Read more about our spectral flow cytometry panel here

About the Speaker

Before Teiko, Ramji was Cofounder, CEO and Chairman of Counsyl, a women’s health genetic screening laboratory. Counsyl screened over 1M prospective parents, mothers-to-be and women at risk of hereditary cancer. In 2018, Counsyl was acquired by Myriad Genetics, Inc for $375M in cash and stock.

Ramji earned a B.S. in computer science and an M.S. in financial mathematics, both from Stanford University. Ramji also attended Stanford’s Graduate School of Business before dropping out to start Counsyl.

You Might Also Like